News Network

  

AAN 2020 Annual Meeting: Epilepsy Highlights


An overview of the GWPCARE5 trial data update presented at the American Academy of Neurology (AAN) 2020 Annual Meeting, regarding the use of cannabidiol to treat patients with Lennox Gastaut Syndrome (LGS). 

An expert in the management of epilepsy discusses the GWPCARE5 data update presented at the American Academy of Neurology (AAN) 2020 Annual Meeting, regarding the use of cannabidiol to treat patients with Dravet syndrome.

An overview of 2 trial updates at the American Academy of Neurology (AAN) 2020 Annual Meeting regarding brain-responsive neurostimulation with the RNS system, and fenfluramine hydrochloride oral solution for Dravet Syndrome.

A key opinion leader discusses the long-term and safety of adjunctive cenobamate in patients with uncontrolled focal seizures.

Elizabeth Thiele, MD, PhD, reviews long-term safety and efficacy data on the use of cannabidiol for children and young adults with Dravet or Lennox-Gastaut syndromes as revealed through an open-label extension study, GWPCARE5, presented at the AAN 2020 Annual Meeting.

An overview of data released at the AAN 2020 Annual Meeting on the safety and efficacy of cannabidiol for the treatment of seizures in patients with tuberous sclerosis complex.

Elizabeth Thiele, MD, PhD, describes what sunflower syndrome is and reacts to the significance of recent data presented on the use of fenfluramine as add-on treatment for children and young adults.

Exciting advances in epilepsy and considerations regarding the use of newer therapies to better manage patients.

Expert perspective on the open-label extension trial that analyzed long-term safety and efficacy with cannabidiol in patients with Lennox-Gastaut syndrome.

Shared insight on the open-label extension trial that analyzed long-term safety and efficacy with cannabidiol in patients with Dravet syndrome.

Considerations for recent data with adjunctive brivaracetam in pediatric patients with primary generalized seizures or mixed seizure types.

An overview of the FREEDOM trial, which tested perampanel monotherapy in the newly diagnosed or currently untreated recurrent partial-onset seizures setting.

Closing thoughts on the remaining gaps in care in epilepsy management, as well as how treatment may advance in the coming years.
SAP Partner Banner